Amyloid ß-peptide and its relationship with dementia in Lewy body disease
Cerebral cortical Lewy bodies occur in a spectrum of clinical syndromes including Parkinson’s disease (PD) with and without dementia, and dementing conditions clinically resembling Alzheimer’s disease with few or without parkinsonian features. It is unclear whether these conditions are variants of one disease process or represent pathogenetically distinct entities. Here we compared the cortical pathology in post mortem brains of three groups representing the predominant clinical phenotypes of Lewy body disease, including 27 non-demented cases of PD, 23 demented PD cases, and 11 cases of Lewy body disease who initially presented with dementia and showed only limited features of parkinsonism during the course of their illness. In addition to neuropathology, computer-assisted histoblot analysis was used to assess cortical amyloid ß-peptide deposition. There was wide overlap of the pathomorphometric features between the two groups of demented cases. It appears that substantial cortical Alzheimer-type pathology present in most demented cases contributes significantly to the development of dementia in Lewy body disease.
KeywordsLewy Body Lewy Body Disease Lewy Body Dementia Diffuse Lewy Body Disease Cortical Lewy Body
Unable to display preview. Download preview PDF.
- American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed, rev. American Psychiatric Association, Washington DC.Google Scholar
- Hansen LA, Galasko D (1992) Lewy body disease. Curr Opin Neuro Neurosurg 5: 889–894.Google Scholar
- Jendroska K, Lees AJ, Poewe W, Daniel SE (1994) Amyloid ß-peptide and its relationship with dementia in Parkinson’s disease. In: Korczyn AD (ed) Dementia in Parkinson’s disease. Monduzzi Editore, Bologna, pp 71–78.Google Scholar
- Lennox G (1992) Lewy body dementia. Ballieres Clin Neurol 1: 653–676.Google Scholar
- McKhann G, Grachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34: 939–44.PubMedCrossRefGoogle Scholar